{"schema":"https://ver.cy/schemas/card/1.0.0","id":"vr.tr.haloxazolam","code":"thing-q4345875","url":"https://ver.cy/models/thing/q4345875/","name":"haloxazolam","alternateNames":[],"kind":"thing","status":"published","version":"0.1.0-research.1","language":"en","classifiers":{"family":"Thing Registry","category":"Physical world and living systems","entryKind":"thing","plane":"PHY","domain":["PHY.MAT"],"industry":[],"navPath":"","tags":[],"facets":{}},"whatItIs":"Haloxazolam is an oxazolobenzodiazepine drug with sedative and hypnotic activity that has been used to treat insomnia.","purpose":"Enable an agent to recognise haloxazolam, assess the identity and fitness of its material samples, and determine which handling or use decisions require further evidence.","scope":{"in":["Molecular identity, identifiers and stereochemical specification","Bulk substance and reference-material composition, purity and grade","Physical properties, stability and storage conditions","Substance-level pharmacology and relationships to metabolites","Hazard evidence and legal conditions affecting possession, transfer and use"],"out":["Somelin and other finished medicinal products, their excipients and packaging","Individual prescribing, dosing, withdrawal management and patient care","Insomnia as a condition and its treatment pathway","Manufacturing routes and production equipment","Independent models of metabolites and other benzodiazepines"],"boundaries":[]},"distinguishingFeatures":["Match the molecular structure and identifiers together: haloxazolam has formula C17H14BrFN2O2, CAS 59128-97-1 and PubChem CID 3563; a similar name alone is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Haloxazolam)","Confirm the brominated, fluorophenyl-substituted fused oxazolo-benzodiazepinone structure rather than accepting any benzodiazepine or a formula-only match. [Japanese Pharmacopoeia XVIII](https://www.mhlw.go.jp/content/11120000/000904440.pdf)","Check stereochemical correspondence to the pharmacopoeial designation (11bRS); an isolated stereoisomer must not silently inherit the same material specification. [Japanese Pharmacopoeia XVIII](https://www.mhlw.go.jp/content/11120000/000904440.pdf)","Distinguish the active substance from a medicine containing it: the cited Somelin label describes tablets and fine granules with haloxazolam plus excipients. [PMDA product label](https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/530258_1124005C1032_2_05)"],"structure":{"bundles":[{"id":"haloxazolam-identity","name":"Haloxazolam identity","description":"Establish the chemical entity behind the registry name.","layers":[{"id":"structure-and-identifiers","name":"Structure and identifiers","description":"Reconcile the registered name with an authoritative molecular identity.","findings":[{"id":"identifier-structure-agreement","name":"Identifier and structure agreement","description":"Require identifiers to resolve to the same haloxazolam structure rather than relying on name similarity.","questions":[{"text":"Which authoritative records connect haloxazolam, CAS 59128-97-1 and PubChem CID 3563 to the same molecular structure?","id":"identifier-structure-agreement-q01","kind":"provenance"},{"text":"Which structural checks distinguish this sample from oxazolam and other similarly named benzodiazepines?","id":"identifier-structure-agreement-q02","kind":"definition"}]}]},{"id":"stereochemistry-and-entity-boundaries","name":"Stereochemistry and entity boundaries","description":"Define correspondence between the registered substance and particular material representations.","findings":[{"id":"stereochemical-material-match","name":"Stereochemical material match","description":"Record whether a material matches the referenced stereochemical specification and whether it is neat substance or a mixture.","questions":[{"text":"What stereochemical composition does the applicable haloxazolam specification require, and what evidence establishes the sample's composition?","id":"stereochemical-material-match-q01","kind":"measurement"},{"text":"Is the record for haloxazolam itself, an isolated stereoisomer, a reference solution or a finished medicine?","id":"stereochemical-material-match-q02","kind":"boundary"}]}]}]},{"id":"haloxazolam-quality","name":"Haloxazolam quality","description":"Determine whether a material is sufficiently characterised for its intended use.","layers":[{"id":"assay-and-grade","name":"Assay and grade","description":"Connect measured content to a declared specification.","findings":[{"id":"content-and-conformity","name":"Content and conformity","description":"Keep assay basis, analytical specificity and specification compliance explicit.","questions":[{"text":"What haloxazolam content was measured, on what mass basis, and does the method distinguish relevant related substances?","id":"content-and-conformity-q01","kind":"measurement"},{"text":"Which specification edition and batch-specific certificate support the claimed grade?","id":"content-and-conformity-q02","kind":"provenance"}]}]},{"id":"impurities-and-reference-traceability","name":"Impurities and reference traceability","description":"Assess related substances, residual materials and the standards used to measure them.","findings":[{"id":"impurity-evidence","name":"Impurity evidence","description":"Document quantified impurities and analytical blind spots rather than treating an assay value as complete purity evidence.","questions":[{"text":"Which haloxazolam-related impurities, residual solvents and water content were tested, and with what reporting limits?","id":"impurity-evidence-q01","kind":"measurement"},{"text":"Which authenticated reference standards establish identity and quantitative traceability for this batch?","id":"impurity-evidence-q02","kind":"provenance"}]}]}]},{"id":"haloxazolam-material-state","name":"Haloxazolam material state","description":"Represent the conditions under which physical-property and stability observations apply.","layers":[{"id":"solid-form-and-thermal-properties","name":"Solid form and thermal properties","description":"Characterise the solid without assuming all haloxazolam samples behave identically.","findings":[{"id":"physical-form-evidence","name":"Physical form evidence","description":"Connect appearance, crystallinity and thermal transitions to a characterised sample.","questions":[{"text":"What observations establish the sample's phase and solid form, and is any polymorph or solvate assignment supported?","id":"physical-form-evidence-q01","kind":"measurement"},{"text":"What melting range or decomposition behaviour is experimentally supported, using which method and sample purity?","id":"physical-form-evidence-q02","kind":"measurement"}]}]},{"id":"solution-and-storage-behaviour","name":"Solution and storage behaviour","description":"Determine when prepared solutions and stored material remain suitable.","findings":[{"id":"preparation-and-stability-window","name":"Preparation and stability window","description":"Require evidence for solvent choice, achievable concentration and retention of chemical identity.","questions":[{"text":"What haloxazolam solubility is measured in the proposed solvent at the relevant temperature and pH?","id":"preparation-and-stability-window-q01","kind":"measurement"},{"text":"What stability evidence supports storage or use of the bulk substance and prepared solution after light, moisture or temperature exposure?","id":"preparation-and-stability-window-q02","kind":"action"}]}]}]},{"id":"haloxazolam-biological-behaviour","name":"Haloxazolam biological behaviour","description":"Connect substance identity with pharmacological evidence while retaining experimental context.","layers":[{"id":"activity-and-effect-evidence","name":"Activity and effect evidence","description":"Separate target-level observations from therapeutic product claims.","findings":[{"id":"pharmacological-attribution","name":"Pharmacological attribution","description":"Attribute receptor activity and hypnotic effects to the tested entity and evidence type.","questions":[{"text":"Which experiments establish haloxazolam's receptor interactions, and what species, assay and concentrations were used?","id":"pharmacological-attribution-q01","kind":"provenance"},{"text":"Which reported effects concern the parent substance, its metabolites or an administered medicinal product?","id":"pharmacological-attribution-q02","kind":"boundary"}]}]},{"id":"metabolism-and-persistence","name":"Metabolism and persistence","description":"Represent transformation and exposure duration without collapsing distinct analytes.","findings":[{"id":"parent-metabolite-discrimination","name":"Parent and metabolite discrimination","description":"Attach metabolic and pharmacokinetic observations to an identified analyte and study population.","questions":[{"text":"Which haloxazolam metabolites have been experimentally identified, and which have demonstrated pharmacological activity?","id":"parent-metabolite-discrimination-q01","kind":"provenance"},{"text":"For each reported half-life or exposure value, which analyte, biological matrix, population and dosing conditions were measured?","id":"parent-metabolite-discrimination-q02","kind":"measurement"}]}]}]},{"id":"haloxazolam-handling-and-controls","name":"Haloxazolam handling and controls","description":"Connect substance-specific hazards and legal identity to proposed actions.","layers":[{"id":"hazard-and-exposure-evidence","name":"Hazard and exposure evidence","description":"Distinguish documented pharmacological risks from bulk-material handling classifications.","findings":[{"id":"risk-context-separation","name":"Risk context separation","description":"The cited product label identifies next-day impairment, dependence and respiratory depression; bulk-material exposure controls require their own evidence. [PMDA product label](https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/530258_1124005C1032_2_05)","questions":[{"text":"Which current substance-specific safety data support GHS classification and occupational exposure controls for the material being handled?","id":"risk-context-separation-q01","kind":"provenance"},{"text":"What controls are justified for weighing powder or handling solutions, and which exposure limits remain unestablished?","id":"risk-context-separation-q02","kind":"action"}]}]},{"id":"jurisdiction-and-use-permissions","name":"Jurisdiction and use permissions","description":"Resolve legal requirements for the substance and the proposed activity.","findings":[{"id":"dated-regulatory-determination","name":"Dated regulatory determination","description":"Record dated authority for possession, transfer, import and use without treating a product label as universal legal permission.","questions":[{"text":"Which current legal instruments identify haloxazolam and establish applicable controls in the origin and destination jurisdictions?","id":"dated-regulatory-determination-q01","kind":"provenance"},{"text":"What authorisations and records are required for the proposed research, supply, import or disposal activity?","id":"dated-regulatory-determination-q02","kind":"action"}]}]}]},{"id":"evidence-and-external-alignment","name":"Evidence and external alignment","description":"What the world already says about this thing, gathered so the model can be checked against it.","layers":[{"id":"reported-evidence","name":"Reported evidence","description":"Findings from the breadth pass, kept separate from the structural claims.","findings":[{"id":"evidence-confidence-notes","name":"Check these first","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these check these first hold for the sense of haloxazolam this model covers, and on what evidence?","id":"evidence-confidence-notes-q01","kind":"provenance"}]},{"id":"evidence-identifiers","name":"Identifiers and schemes","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these identifiers and schemes hold for the sense of haloxazolam this model covers, and on what evidence?","id":"evidence-identifiers-q01","kind":"provenance"}]},{"id":"evidence-real-world-use","name":"Real-world use","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these real-world use hold for the sense of haloxazolam this model covers, and on what evidence?","id":"evidence-real-world-use-q01","kind":"provenance"}]},{"id":"evidence-failure-modes-and-hazards","name":"Failure modes and hazards","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these failure modes and hazards hold for the sense of haloxazolam this model covers, and on what evidence?","id":"evidence-failure-modes-and-hazards-q01","kind":"provenance"}]},{"id":"evidence-regional-variation","name":"Regional variation","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these regional variation hold for the sense of haloxazolam this model covers, and on what evidence?","id":"evidence-regional-variation-q01","kind":"provenance"}]},{"id":"evidence-neighbours","name":"Neighbouring kinds and how to tell them apart","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these neighbouring kinds and how to tell them apart hold for the sense of haloxazolam this model covers, and on what evidence?","id":"evidence-neighbours-q01","kind":"provenance"}]}]}]}]},"agentConduct":{"may":["Describe haloxazolam's class, sedative effects and use for insomnia where licensed.","Explain dependence and withdrawal risks of benzodiazepines in general terms."],"mustNot":["Recommend, dose or supply it to a person without a prescriber's decision.","Assist in giving it to anyone without their knowledge.","Advise combining it with alcohol, opioids or other sedatives.","Help obtain it outside lawful supply channels."],"requiresHuman":["Any decision to start, stop or taper treatment."]},"ethics":{"considerations":["Sedatives can be misused to incapacitate people; covert dosing is a serious crime.","Long-term use causes dependence that patients must be warned about."],"affectedParties":["Patients with insomnia","Older people at risk of falls","Potential victims of covert dosing"]},"owners":{"steward":"The marketing authorisation holder where it is licensed; the prescriber answers for each use.","roles":[],"masterSystems":["National medicines registers","National controlled substance schedules"]},"relations":[{"target":"Q11173","type":"parent","note":"registry parent class"}],"interaction":{"identity":{"applicability":"required","items":["Vercy registry: vr.tr.haloxazolam","Wikidata: Q4345875 (https://www.wikidata.org/wiki/Q4345875)"]},"properties":{"applicability":"required","items":["Molecular identity: Structure representation, stereochemical designation, CAS and PubChem identifiers","Assay and reporting basis: % mass fraction; as-is or dried basis; method and uncertainty","Impurity profile: Individual and total impurities in % or mg/kg; detection and quantification limits","Material grade: Pharmacopoeial substance, analytical reference material, research material or unverified; specification edition","Physical form: Observed phase, crystallinity, solid-form assignment and measurement conditions","Thermal behaviour: Melting range or decomposition onset in °C; method; pressure where relevant","Solubility: mg/mL or mol/L with solvent, temperature, pH and equilibration method","Stability status: Within supported storage conditions, excursion pending assessment, degraded or unknown","Pharmacological and metabolic relationships: Target, effect and metabolite links with species, assay and evidence source","Hazard and regulatory applicability: GHS classification, exposure-limit status and controlled-substance status, each with jurisdiction, source and date"]},"recognition":{"applicability":"required","items":["Identity cannot be settled by sight; tablets must be confirmed by label and pharmacy records."]},"capabilities":{"applicability":"required","items":["Resolve a named substance or sample against haloxazolam identifiers and structural evidence.","Compare a batch certificate and analytical results with its declared grade.","Assess whether a proposed analytical solvent and storage condition have supporting evidence.","Link haloxazolam to containing products and reported metabolites without merging their identities.","Flag unsupported handling or transfer decisions for chemical-safety or regulatory review."]},"hazards":{"applicability":"required","items":["Dependence, withdrawal and rebound insomnia.","Drowsiness, falls and impaired driving.","Dangerous breathing suppression when combined with other sedatives."]},"interfaces":{"applicability":"required","items":["Convention on Psychotropic Substances 1971, Schedule IV, United Nations."]},"context":{"applicability":"required","items":["Haloxazolam is encountered in pharmaceutical contexts as a sedative and hypnotic compound that has been used to treat insomnia.","It is also encountered in analytical and pharmacological research concerning compound identity, drug action and metabolism."]}},"sources":[{"title":"Wikidata item Q4345875: haloxazolam","url":"https://www.wikidata.org/wiki/Q4345875","note":"identity and sense of the item"},{"title":"Wikipedia: Haloxazolam","url":"https://en.wikipedia.org/wiki/Haloxazolam","note":"general description of the item"}],"openQuestions":["Which current pharmacopoeial edition governs haloxazolam identity, assay, stereochemical specification and impurity acceptance criteria?","Which solid forms, melting or decomposition measurements and quantitative solubility values have reliable experimental support, and is a boiling-point value physically meaningful?","Which metabolites and human pharmacokinetic measurements establish the respective contributions of parent substance and metabolites to persistence?","What current bulk-substance SDS, GHS classifications, occupational exposure limits and EC identifier, if any, can be verified?","Which storage conditions, retest periods and jurisdiction-specific legal permissions are supported for the particular grade and intended activity?"],"resources":{"spec":"/models/things/publications/thing-q4345875/spec.json"},"provenance":{"origin":"thing registry research (pass 2)","builtFrom":["models/things/publications/thing-q4345875/spec.json"],"providers":["Codex"],"researchStatus":"unreviewed","generatedAt":"2026-09-12T10:11:12Z","builder":"tools/build_cards.py@1.0.0"},"completeness":{"sections":{"classifiers":"filled","whatItIs":"filled","purpose":"filled","distinguishingFeatures":"filled","structure":"filled","agentConduct":"filled","ethics":"filled","owners":"filled","relations":"filled","interaction.identity":"filled","interaction.properties":"filled","interaction.recognition":"filled","interaction.capabilities":"filled","interaction.hazards":"filled","interaction.interfaces":"filled","interaction.context":"filled","sources":"filled"},"notes":{"_gate":"Published through the thing publication gate 1.0 on 2026-10-07T10:10:31+00:00: completeness 1.00; sense: Wikidata description; 2 live sources; review by codex: pass"},"score":1.0}}